2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2567

Clinically Meaningful Improvement in Skin and Nail Psoriasis in Bio-Naïve Active Psoriatic Arthritis Patients Treated with Intravenous Golimumab: Results through Week 24 from a Phase 3 Study
Abstract Number: 2568

Secukinumab Provides Sustained Improvements in the Signs and Symptoms in Psoriatic Arthritis: Final 5 Year Efficacy and Safety Results from a Phase 3 Trial
Abstract Number: 2569

Association of Enthesitis with Achievement of Normal Quality of Life and Clinical Response in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Adalimumab
Abstract Number: 2570

Probability of Achieving Low Disease Activity or Remission in Subjects with Active Psa Treated with Apremilast
Abstract Number: 2571

Adalimumab Serum Concentration Fails to Predict Achievement of Sustained Remission or Absence of Flare for Patients with Non-Radiographic Axial Spondyloarthritis
Abstract Number: 2572

Predictors for Use of Secukinumab 300mg over 150mg in Psoriatic Arthritis: A Meta-Analysis of Four Phase 3 Trials By Machine Learning
Abstract Number: 2573

The Effect of Biologic Disease-Modifying Antirheumatic Drugs in Targeting Disease Remission in Axial Spondyloarthritis: A Systematic Literature Review
Abstract Number: 2574

Tapering TNF Inhibitors in Axial Spondyloarthritis: Systematicanalysisoftheliteratureandmeta-Analysis
Abstract Number: 2575

Long-Term Effects of TNF-Alpha Inhibitors on Bone Mineral Density and the Incidence of Vertebral Fractures in Patients with Ankylosing Spondylitis
Abstract Number: 2576

Anti-Drug Antibodies, Efficacy, and Impact of Concomitant Methotrexate in Ixekizumab-Treated Patients with Psoriatic Arthritis
Abstract Number: 2577

Long-Term Effect of Ixekizumab on Patient-Reported Outcomes in Patients with Psa and Inadequate Response to TNF Inhibitors: 2-Year Follow-up from a Phase 3 Study
Abstract Number: 2578

Exposure Response Analyses to Describe the Relationship between Ixekizumab Concentrations and Acr Responses in Psoriatic Arthritis Patients
Abstract Number: 2579

Ixekizumab Treatment Significantly Improves Enthesitis and Dactylitis in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Trials
Abstract Number: 2580

Predicting Treatment Persistence and Non-Persistence of Newly Initiated TNF Inhibitor Therapy in Ankylosing Spondylitis Patients: A Gender Comparison
Abstract Number: 2581

Comparing Treatment Patterns of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].